Previous 10 | Next 10 |
Companies engaged in developing therapies for Alzheimer's disease were among the best performing biotech stocks in the first half of the year.Cassava Sciences ([[SAVA]] -1.7%) was the best performing biotech stock in the half, with a return in the period of 1166%.A phase 3 trial of its Alzhei...
Marcelo Ricardo Daros/iStock via Getty Images Adding more than a quarter of its value today so far, clinical-stage biopharmaceutical company Graybug Vision ([[GRAY]] +26.5%) is on course to record its biggest one-day gain since December. ~19.2M Graybug shares have changed hands today, indicat...
Gainers: Intellia Therapeutics (NTLA) +39%, Verve Therapeutics (VERV) +29%, Graybug Vision (GRAY) +24%, Anavex Life Sciences (AVXL) +15%, ReShape Lifesciences (RSLS) +13%.Losers: CEL-SCI (CVM) -38%, Acurx Pharmaceuticals (ACXP) -22%, Exelixis ...
Gainers: Enochian Biosciences ENOB +127%, RAPT Therapeutics RAPT +101%, iTeos Therapeutics ITOS +37%, Novan NOVN +30%, Anavex Life Sciences AVXL +23%.Losers: Avenue Therapeutics ATXI -39%, Inhibikase Therapeutics (IKT) -21%, ...
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...
Gainers: Ra Medical Systems (RMED) +67%, Nemaura Medical (NMRD) +23%, Lucira Health (LHDX) +21%, Minerva Neurosciences (NERV) +20%, Harrow Health (HROW) +19%.Losers: InflaRx (IFRX) -15%, Praxis Precision Medicines (PRAX) -14%, Lianlu...
Graybug Vision ([[GRAY]] -7.2%) has reported the results from full-data analysis of the Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD).Conducted across 33 sites in the U.S., the masked and controlled trial was designed to evalu...
Graybug Vision (GRAY): Q1 GAAP EPS of -$0.54 misses by $0.08.As of March 31, 2021, the company’s cash, cash equivalents, and short-term investments totaled $85.7 million, compared to $95.0 million as of December 31, 2020. The decrease was primarily due to the loss from operations of $1...
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate dev...
GB-102 1mg has shown competitive durability and anatomical control versus aflibercept Trend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patients Developing enhanced formulations and seeking partner funding for additional clinical ...
News, Short Squeeze, Breakout and More Instantly...
Graybug Vision Inc. Company Name:
GRAY Stock Symbol:
NASDAQ Market:
- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 - Phase 2b results ...
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its tradin...
Toronto, Ontario--(Newsfile Corp. - March 2, 2023) - Graycliff Exploration Limited (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) (the " Company " or " Graycliff ") is pleased to announce that it has acquired the Lunge Project ("Lunge") located on the prolific Canadian Shield in the Sudbury Basin...